secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0001619856-25-000023
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou cuts 32% workforce, discontinues lupus/AML trials, cash runway to H2 2027
--------------------------------------------------------------------------------

- Workforce reduction of 47 employees (~32%), expected completion by Q2 2025.
- Preliminary cash, equivalents & marketable securities of $212.5M as of March 31, 2025.
- Discontinued GALLOP (lupus), AMpLify (AML) trials & preclinical research to focus on CB-010 & CB-011.
- Estimated restructuring costs of $2.5-3.5M, primarily severance and trial wind-down.
- Cash runway extended one year to H2 2027; CB-010 & CB-011 data readouts planned for H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/0001619856-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/crbu-20250424.htm
  HTML page:      https://secwatch.observer/filing/0001619856-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer